The advent of monoclonal antibodies targeting programmed cell death-1 (PD1) or its ligand (PD-L1) has brought about a revolutionary shift in the management of advanced non-small cell lung cancer (NSCLC), with several studies demonstrating notable improvements in objective response rate (ORR), progression-free survival (PFS), and overall survival (OS).1 The gene discussed is PDCD1; the disease is non-small cell lung carcinoma.